Diagnostics And Therapeutics For Lung Cancer Market By Drug (Angiogenesis Inhibitor, EGFR Blockers, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, PD-1/PD-L1 Inhibitor), Industry Size, Growth, Share And Forecast To 2022
Key Findings
The global diagnostics and therapeutics for lung cancer market is expected to grow at the CAGR of 8% during 2015-2022. The global diagnostics and therapeutics for lung cancer market would be driven by increasing adoption of personalized treatments. Lung cancer also called pulmonary carcinoma is a type of cancer characterized by uncontrolled cell growth in the lungs. There are two types of lung cancer: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC); where over 80% of the lung cancers are NSCLC. These are differentiated based on their size as view under the microscope. Lung cancer is one of the most prevalent cancers and also has the highest mortality rate as compared to other cancers.
Market Segment Insights
The application market for Diagnostics and Therapeutics for Lung Cancer market is segmented as follows: by drug type and by geography. The biggest segment of the market currently is Angiogenesis inhibitor. The folate antimetabolites segment will be the next highest segment of the global Non-Small Cell Lung Cancer therapeutics market. The EGFR inhibitor and microtubule stabilizer segments hold significant market shares of the market in terms of revenue. However, entry of new targeted therapies with more surveillance rate could restrain market growth. PD- Since affectivity of the treatment as clinical data showed double survival rates, 1/PD-L1 inhibitor is the most promising segment in terms of growth during the forecast period.
Regional Insights
Globally, North America dominates the global diagnostics and therapeutics for lung cancer market, The global NSCLC therapeutics market has been categorized into North America Europe Asia Pacific and Rest of the World.
Competitive Insights
The key players in the global diagnostics and therapeutics for lung cancer market include Genentech, Inc. ( a Roche Company), Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Pfizer, Inc., Novartis AG, Astra Zeneca plc, and Celgene Corporation.
Reasons for Buying the Report
- This report provides a detailed study of current trends in the global diagnostics and therapeutics for lung cancer market, key growth drivers, and restraints.
- It provides market forecast for the next 7 years (2015-2022) assessed on the basis of market growth.
- The report also includes analysis of recent technological developments in the global diagnostics and therapeutics for lung cancer market, analysis of key market players and the key winning strategy adopted and predictive analysis.
- The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
- The report tracks and analyse the changing market dynamics.
- The report also talks about emerging opportunities in the market and the future impact of major drivers and restraints of the market.
- The report also provides extensive analysis with respect to key product segments.
- The analysis in the report will help in making effective business decisions.
- It provides analysis through distinctive graphs and charts and analyses strengths, weakness, opportunities and threats of major market players.
1. Methodology & Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
2. Executive Summary
2.1. Global Diagnostics and Therapeutics for Lung Cancer market – Industry summary & key buying criteria
2.2. Global Diagnostics and Therapeutics for Lung Cancer industry outlook
2.3. Market segmentation analysis
2.4. Market size and growth prospects, 2012-2022
2.5. Global Diagnostics and Therapeutics for Lung Cancer value chain analysis
2.6. Vendor Landscape
3. Global Diagnostics and Therapeutics for Lung Cancer market dynamics
3.1. Market driver analysis
3.1.1. Innovative targeted therapy drugs to drive the market for lung cancer
3.1.2. Introduction of new ingredients in sports nutrition products
3.1.3. Rising incidence of lung cancer to drive the market for drugs
3.2. Market restraint analysis
3.3. Key opportunities prioritized
4. Industry analysis
4.1. Global Diagnostics and Therapeutics for Lung Cancer market Porter’s analysis
4.2. Global Diagnostics and Therapeutics for Lung Cancer market – PESTEL analysis
4.3. Global Diagnostics and Therapeutics for Lung Cancer market – GAP analysis
5. Global Diagnostics and Therapeutics for Lung Cancer market by drug Type, 2012 - 2022 ($ BILLION)
5.1. Global Angiogenesis Inhibitor market, 2012 - 2022 ($ BILLION)
5.2. Global EGFR Blockers market, 2012 - 2022 ($ BILLION)
5.3. Global Kinase Inhibitor market, 2012 - 2022 ($ BILLION)
5.4. Global Microtubule Stabilizermarket, 2012 - 2022 ($ BILLION)
5.5. Global Folate Antimetabolites market, 2012 - 2022 ($ BILLION)
5.6. Global PD-1/PD-L1 Inhibitor market, 2012 - 2022 ($ BILLION)
6. Global Diagnostics and Therapeutics for Lung Cancer market, regional outlook, 2012-2022 ($ BILLION)
6.1. Global Diagnostics and Therapeutics for Lung Cancer market volume share by region, 2012 - 2022 ($ BILLION)
6.1.1. North America
6.1.1.1. North America market estimates and forecast, 2012 – 2022($ BILLION)
6.1.1.2. North America market estimates and forecast by region, 2012 – 2022($ BILLION
6.1.1.3. North America market estimates and forecast by drug type, 2012 – 2022($ BILLION)
6.1.1.4. U.S.
6.1.1.4.1. U.S. market estimates and forecast, 2012 – 2022($ BILLION)
6.1.1.4.2. U.S. market estimates and forecast by drug type, 2012 – 2022($ BILLION)
6.1.1.5. Canada
6.1.1.5.1. Canada market estimates and forecast, 2012 – 2022($ BILLION)
6.1.1.5.2. Canada market estimates and forecast by drug type, 2012 – 2022($ BILLION)
6.1.1.6. Mexico
6.1.1.6.1. Mexico market estimates and forecast, 2012 – 2022($ BILLION)
6.1.1.6.2. Mexico market estimates and forecast by drug type, 2012 – 2022($ BILLION)
6.1.2. Europe
6.1.2.1. Europe market estimates and forecast, 2012 – 2022($ BILLION)
6.1.2.2. Europe market estimates and forecast by region, 2012 – 2022($ BILLION)
6.1.2.3. Europe market estimates and forecast by drug type, 2012 – 2022($ BILLION)
6.1.2.4. Germany
6.1.2.4.1. Germany market estimates and forecast, 2012 – 2022($ BILLION)
6.1.2.4.2. Germany market estimates and forecast by drug type, 2012 – 2022($ BILLION)
6.1.2.5. UK
6.1.2.5.1. UK market estimates and forecast, 2012 – 2022($ BILLION)
6.1.2.5.2. UK market estimates and forecast by drug type, 2012 – 2022($ BILLION)
6.1.2.6. Russia
6.1.2.6.1. Russia market estimates and forecast, 2012 – 2022($ BILLION)
6.1.2.6.2. Russia market estimates and forecast by drug type, 2012 – 2022($ BILLION)
6.1.3. Asia Pacific
6.1.3.1. Asia Pacific market estimates and forecast, 2012 – 2022($ BILLION)
6.1.3.2. Asia Pacific market estimates and forecast by region, 2012 – 2022($ BILLION)
6.1.3.3. Asia Pacific market estimates and forecast by drug type, 2012 – 2022($ BILLION)
6.1.3.4. China
6.1.3.4.1. China market estimates and forecast, 2012 – 2022($ BILLION)
6.1.3.4.2. China market estimates and forecast by drug type, 2012 – 2022($ BILLION)
6.1.3.5. India
6.1.3.5.1. India market estimates and forecast, 2012 – 2022($ BILLION)
6.1.3.5.2. India market estimates and forecast by drug type, 2012 – 2022($ BILLION)
6.1.3.6. South Korea
6.1.3.6.1. South Korea market estimates and forecast, 2012 – 2022($ BILLION)
6.1.3.6.2. South Korea market estimates and forecast by drug type, 2012 – 2022($ BILLION)
6.1.4. Middle East & Africa
6.1.4.1. Middle East & Africa market estimates and forecast, 2012 – 2022($ BILLION)
6.1.4.2. Middle East & Africa market estimates and forecast by drug type, 2012 – 2022($ BILLION)
6.1.5. Central &South America
6.1.5.1. Central & South America market estimates and forecast, 2012 – 2022($ BILLION)
6.1.5.2. Central & South America market estimates and forecast by drug type, 2012 – 2022($ BILLION)
6.1.6. Brazil
6.1.6.1. Brazil market estimates and forecast, 2012 – 2022($ BILLION)
6.1.6.2. Brazil market estimates and forecast by drug type, 2012 – 2022($ BILLION)
7. Competitive Landscape
7.1. Astra Zeneca PLC.
7.1.1. Company Overview
7.1.2. Financial Performance
7.1.3. Product Benchmarking
7.1.4. Strategic Initiatives
7.2. Boehringer Ingelheim
7.2.1. Company Overview
7.2.2. Financial Performance
7.2.3. Product Benchmarking
7.2.4. Strategic Initiatives
7.3. Bristol-Myers Squibb.
7.3.1. Company Overview
7.3.2. Financial Performance
7.3.3. Product Benchmarking
7.3.4. Strategic Initiatives
7.4. Celgene Corporation
7.4.1. Company Overview
7.4.2. Financial Performance
7.4.3. Product Benchmarking
7.4.4. Strategic Initiatives
7.5. GlaxoSmithKline PLC.
7.5.1. Company Overview
7.5.2. Financial Performance
7.5.3. Product Benchmarking
7.5.4. Strategic Initiatives
7.6. Eli Lilly & Co
7.6.1. Company Overview
7.6.2. Financial Performance
7.6.3. Product Benchmarking
7.6.4. Strategic Initiatives
7.7. Eli Lilly & Co
7.7.1. Company Overview
7.7.2. Financial Performance
7.7.3. Product Benchmarking
7.7.4. Strategic Initiatives
7.8. Genentech, Inc. (a Roche company)
7.8.1. Company Overview
7.8.2. Financial Performance
7.8.3. Product Benchmarking
7.8.4. Strategic Initiatives
7.9. Sun Pharmaceutical Industries Ltd.
7.9.1. Company Overview
7.9.2. Financial Performance
7.9.3. Product Benchmarking
7.9.4. Strategic Initiatives
TABLE 1 YEARLY COST OF DRUGS,
TABLE 2 DOSAGE PATTERNS OF DRUGS
TABLE 3 LUNG CANCER DRUGS MARKET REVENUE, BY DRUGS, 2012-2022($MILLION)
TABLE 4 LUNG CANCER STAGES & TUMOR SIZE
TABLE 5 LUNG CANCER STAGES, TREATMENT OPTIONS & SURVIVAL RATES
TABLE 6 LUNG CANCER DRUGS – PATENT STATUS
TABLE 7 LUNG CANCER DRUGS MARKET REVENUE, BY DRUGS, 2012-2022($MILLION)
TABLE 8 LUNG CANCER DRUGS (HYCAMTIN) MARKET REVENUE, BY COUNTRY, 2012-2022($MILLION)
TABLE 9 LUNG CANCER DRUGS (TAXOTERE) MARKET REVENUE, BY COUNTRY, 2012-2022($MILLION)
TABLE 10 LUNG CANCER DRUGS (GEMZAR) MARKET REVENUE, BY COUNTRY, 2012-2022($MILLION)
TABLE 11 LUNG CANCER DRUGS (ALIMTA) MARKET REVENUE, BY COUNTRY, 2012-2022($MILLION)
TABLE 12 LUNG CANCER DRUGS (IRESSA) MARKET REVENUE, BY COUNTRY, 2012-2022($MILLION)
TABLE 13 LUNG CANCER DRUGS (AVASTIN) MARKET REVENUE, BY COUNTRY, 2012-2022($MILLION)
TABLE 14 LUNG CANCER DRUGS (TARCEVA) MARKET REVENUE, BY COUNTRY, 2012-2022($MILLION)
1. Global Diagnostics and therapeutics for lung cancer market share, 2012 - 2022 ($ BILLION)
2. Market Share by regions
3. United States market estimates and forecast, 2012 – 2022 ($ BILLION)
4. Canada market estimates and forecast, 2012 – 2022 ($ BILLION)
5. Mexico market estimates and forecast, 2012 – 2022 ($ BILLION)
6. UK market estimates and forecast, 2012 – 2022 ($ BILLION)
7. France market estimates and forecast, 2012 – 2022 ($ BILLION)
8. Germany market estimates and forecast, 2012 – 2022 ($ BILLION)
9. APAC market estimates and forecast, 2012 – 2022($ BILLION)
10. China market estimates and forecast, 2012 – 2022 ($ BILLION)
11. India market estimates and forecast, 2012 – 2022 ($ BILLION)
12. Middle East & Africa market estimates and forecast, 2012 – 2022 ($ BILLION)
13. Central & South America market estimates and forecast, 2012 – 2022($ BILLION)
14. Brazil market estimates and forecast, 2012 – 2022 ($ BILLION)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)